Tirzepatide achieves greatest fat mass reduction but also significant lean mass loss among antidiabetic drugs
Background
Antidiabetic drugs vary significantly in their impact on body composition, which is crucial for overall metabolic health and functional outcomes. While many agents promote weight loss, the specific changes in fat mass (FM) versus lean body mass (LBM) can differ, influencing long-term benefits and potential side effects. Current standard-of-care often focuses on glycemic control and total weight, but understanding the nuanced effects on FM and LBM is vital for optimizing treatment strategies, particularly in patients with type 2 diabetes or obesity.
Study Design
This systematic review and network meta-analysis (NMA) quantified and compared the effects of major antidiabetic drugs on body composition. Researchers searched PubMed, Web of Science, and Scopus for randomized controlled trials (RCTs) from inception to March 2025. The NMA utilized a frequentist random-effects framework to estimate mean differences (MDs) and 95% confidence intervals (CIs) for changes in FM and LBM. The analysis included 41 trials involving 2906 participants, comparing various antidiabetic agents against placebo or other active comparators.
Results
Among GLP-1 and dual GIP/GLP-1 receptor agonists, tirzepatide demonstrated the most substantial fat mass reduction compared to placebo.
Tirzepatide reduced fat mass by MD -10.70 kg (95% CI: -13.42 to -7.99), followed by liraglutide plus exercise. Semaglutide and liraglutide alone produced moderate FM reductions. In contrast, insulin glargine and alogliptin were associated with FM gain relative to metformin and exenatide. For lean body mass, tirzepatide also showed a significant reduction of MD -4.40 kg (95% CI: -7.58 to -1.22), and liraglutide reduced LBM by MD -1.54 kg (95% CI: -2.55 to -0.52). Sodium-glucose cotransporter-2 (
SGLT2) inhibitors caused minor LBM losses, whereas metformin, insulin regimens, and dipeptidyl peptidase-4 (DPP4) inhibitors exhibited neutral effects on LBM.
Key Findings
- Tirzepatide achieved the greatest fat mass reduction (MD -10.70 kg; 95% CI: -13.42 to -7.99) compared to placebo.
- Tirzepatide also caused significant lean body mass loss (MD -4.40 kg; 95% CI: -7.58 to -1.22).
- Liraglutide plus exercise showed the second-highest fat mass reduction, suggesting exercise mitigates LBM loss.
- Liraglutide alone reduced lean body mass by MD -1.54 kg (95% CI: -2.55 to -0.52).
- Insulin glargine and alogliptin were associated with fat mass gain relative to metformin and exenatide.
Why It Matters
This meta-analysis highlights that while highly effective weight loss agents like tirzepatide and liraglutide significantly reduce fat mass, they also lead to notable lean body mass loss. Optimizing body composition during weight loss is crucial, suggesting that patients using these powerful peptides may benefit from concurrent strategies like resistance training and adequate protein intake to preserve muscle mass. For biohackers and clinicians, this implies that total weight loss alone isn't the sole metric; the quality of weight loss (fat vs. muscle) is paramount for long-term metabolic health and functional capacity. The finding that exercise mitigated liraglutide-related LBM loss provides a clear actionable insight for protocol design.
tirzepatide
liraglutide
semaglutide
glp-1-agonist
gip-agonist
body-composition